Table 2.
Characteristics | HR (95% CI) | P-value |
---|---|---|
| ||
Lactate dehydrogenase (U/L) | .015 | |
<245 | Reference | |
≥245 | 1.491 (1.081–2.057) | |
No. of metastatic sites | .050 | |
Single | Reference | |
Multiple | 1.429 (1.000–2.047) | |
Liver metastasis | <.001 | |
No | Reference | |
Yes | 2.319 (1.254–4.291) | |
Posttreatment EBV DNA | <.001 | |
Undetectable | Reference | |
Detectable | 1.923 (1.406–2.630) | |
Response of metastasis | ||
Complete response | Reference | |
Partial response | 1.668 (0.839–3.316) | .144 |
Stable disease | 2.813 (1.373–5.762) | .005 |
Progression disease | 6.607 (3.025–14.429) | <.001 |
Abbreviations: CI = confidence interval; EBV = Epstein—Barr virus; HR = hazard ratio.
Variables with a P < .1 in the univariate analyses were entered into a stepwise multivariate Cox regression analysis. Model selection was made based on a stepwise method using the Akaike information criterion as a stop rule. The Akaike information criterion of the final model was 1838.2.